175 related articles for article (PubMed ID: 37710322)
1. Incidence and prevalence of neurofibromatosis type 1 and 2: a systematic review and meta-analysis.
Lee TJ; Chopra M; Kim RH; Parkin PC; Barnett-Tapia C
Orphanet J Rare Dis; 2023 Sep; 18(1):292. PubMed ID: 37710322
[TBL] [Abstract][Full Text] [Related]
2. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
3. Progress toward the isolation and characterization of the genes causing neurofibromatosis.
Menon AG; Gusella JF; Seizinger BR
Brain Pathol; 1990 Sep; 1(1):33-40. PubMed ID: 1669691
[TBL] [Abstract][Full Text] [Related]
4. Prevalence of neurofibromatosis type 1 in the Finnish population.
Kallionpää RA; Uusitalo E; Leppävirta J; Pöyhönen M; Peltonen S; Peltonen J
Genet Med; 2018 Sep; 20(9):1082-1086. PubMed ID: 29215653
[TBL] [Abstract][Full Text] [Related]
5. COVID-19 in people with neurofibromatosis 1, neurofibromatosis 2, or schwannomatosis.
Banerjee J; Friedman JM; Klesse LJ; Yohay KH; Jordan JT; Plotkin SR; Allaway RJ; Blakeley JO
Genet Med; 2023 Feb; 25(2):100324. PubMed ID: 36565307
[TBL] [Abstract][Full Text] [Related]
6. [Seizures in neurofibromatosis. What is the risk?].
Drouet A
Rev Neurol (Paris); 2011 Dec; 167(12):886-96. PubMed ID: 22041820
[TBL] [Abstract][Full Text] [Related]
7. Incidence of tethered cord syndrome in neurofibromatosis types 1 and 2 pediatric patients: a population-level analysis.
Bhanja D; Freedman Z; Sciscent BY; Moeckel C; Daggubati L; Rizk E
Childs Nerv Syst; 2024 Jun; 40(6):1821-1825. PubMed ID: 38451296
[TBL] [Abstract][Full Text] [Related]
8. Neurofibromatosis-associated nerve sheath tumors. Case report and review of the literature.
Murovic JA; Kim DH; Kline DG
Neurosurg Focus; 2006 Jan; 20(1):E1. PubMed ID: 16459989
[TBL] [Abstract][Full Text] [Related]
9. [Neurofibromatosis].
Wolkenstein P; Decq P
Neurochirurgie; 1998 Nov; 44(4):267-72. PubMed ID: 9864698
[TBL] [Abstract][Full Text] [Related]
10. Prevalence of neurofibromatosis 1 in German children at elementary school enrollment.
Lammert M; Friedman JM; Kluwe L; Mautner VF
Arch Dermatol; 2005 Jan; 141(1):71-4. PubMed ID: 15655144
[TBL] [Abstract][Full Text] [Related]
11. Clinical and molecular characterization of neurofibromatosis in southern Brazil.
Rosset C; Vairo F; Cristina Bandeira I; Fonini M; Netto CBO; Ashton-Prolla P
Expert Rev Mol Diagn; 2018 Jun; 18(6):577-586. PubMed ID: 29685074
[TBL] [Abstract][Full Text] [Related]
12. Bone Mineral Density in Neurofibromatosis Type 1: A Systematic Review and Meta-Analysis.
Charoenngam N; Wattanachayakul P; Jaroenlapnopparat A; Ungprasert P; Chenbhanich J
Calcif Tissue Int; 2023 Aug; 113(2):166-174. PubMed ID: 37221347
[TBL] [Abstract][Full Text] [Related]
13. Advances in the treatment of neurofibromatosis-associated tumours.
Lin AL; Gutmann DH
Nat Rev Clin Oncol; 2013 Nov; 10(11):616-24. PubMed ID: 23939548
[TBL] [Abstract][Full Text] [Related]
14. Nonsteroidal sulfamate derivatives as new therapeutic approaches for Neurofibromatosis 2 (NF2).
Shen YC; Arellano-Garcia C; Menjivar RE; Jewett EM; Dohle W; Karchugina S; Chernoff J; Potter BVL; Barald KF
BMC Pharmacol Toxicol; 2019 Nov; 20(1):67. PubMed ID: 31730023
[TBL] [Abstract][Full Text] [Related]
15. Optimizing biologically targeted clinical trials for neurofibromatosis.
Gutmann DH; Blakeley JO; Korf BR; Packer RJ
Expert Opin Investig Drugs; 2013 Apr; 22(4):443-62. PubMed ID: 23425047
[TBL] [Abstract][Full Text] [Related]
16. Comparison of Cancer Prevalence in Patients With Neurofibromatosis Type 1 at an Academic Cancer Center vs in the General Population From 1985 to 2020.
Landry JP; Schertz KL; Chiang YJ; Bhalla AD; Yi M; Keung EZ; Scally CP; Feig BW; Hunt KK; Roland CL; Guadagnolo A; Bishop AJ; Lazar AJ; Slopis JM; McCutcheon IE; Torres KE
JAMA Netw Open; 2021 Mar; 4(3):e210945. PubMed ID: 33734413
[TBL] [Abstract][Full Text] [Related]
17. Neurofibromatosis and associated tumour suppressor genes.
Zwarthoff EC
Pathol Res Pract; 1996 Jul; 192(7):647-57. PubMed ID: 8880865
[TBL] [Abstract][Full Text] [Related]
18. Ultrasound assessment of peripheral nerve pathology in neurofibromatosis type 1 and 2.
Winter N; Rattay TW; Axer H; Schäffer E; Décard BF; Gugel I; Schuhmann M; Grimm A
Clin Neurophysiol; 2017 May; 128(5):702-706. PubMed ID: 28315612
[TBL] [Abstract][Full Text] [Related]
19. Neurofibromatosis from Head to Toe: What the Radiologist Needs to Know.
Wang MX; Dillman JR; Guccione J; Habiba A; Maher M; Kamel S; Panse PM; Jensen CT; Elsayes KM
Radiographics; 2022; 42(4):1123-1144. PubMed ID: 35749292
[TBL] [Abstract][Full Text] [Related]
20. Lessons learned from drug trials in neurofibromatosis: A systematic review.
Dhaenens BAE; Ferner RE; Evans DG; Heimann G; Potratz C; van de Ketterij E; Kaindl AM; Hissink G; Carton C; Bakker A; Nievo M; Legius E; Oostenbrink R
Eur J Med Genet; 2021 Sep; 64(9):104281. PubMed ID: 34237445
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
